Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
Novartis
Novartis
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Stanford University
National Institutes of Health Clinical Center (CC)
CRISPR Therapeutics
H. Lee Moffitt Cancer Center and Research Institute
City of Hope Medical Center
Thomas Jefferson University
Takeda
Incyte Corporation
Massachusetts General Hospital
Massachusetts General Hospital
Columbia University
Dana-Farber Cancer Institute
Institute of Hematology & Blood Diseases Hospital, China
Abramson Cancer Center at Penn Medicine
AIDS Malignancy Consortium